1. MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2005
NET PRODUCT SALES DETAIL (millions of dollars)
2Q `05 vs. 2Q `04
TOTAL TOTAL U.S. U.S. Foreign Foreign
PRODUCT % CHG $ % CHG $ % CHG $
AGGRASTAT 9% 23 N/A - 9% 23
ARCOXIA -19% 50 N/A - -19% 50
CANCIDAS 38% 140 29% 75 51% 65
COZAAR / HYZAAR 8% 785 - 260 13% 525
CRIXIVAN / STOCRIN 38% 89 73% 10 34% 78
EMEND * 19 96% 17 * 3
FOSAMAX 8% 853 9% 476 6% 377
INVANZ 41% 22 23% 14 85% 8
MAXALT 6% 84 4% 53 10% 31
PRIMAXIN 19% 181 39% 51 12% 131
PROPECIA 6% 69 -2% 32 14% 37
PROSCAR 2% 188 -1% 94 5% 94
SINGULAIR 14% 730 8% 489 27% 241
TIMOPTIC / TIMOPTIC XE -6% 37 15% 3 -7% 34
TRUSOPT / COSOPT 15% 153 2% 59 25% 94
VASOTEC / VASERETIC -16% 164 N/A - -16% 164
VIOXX * - * - * -
ZOCOR -16% 1,151 -15% 814 -18% 337
HEPATITIS VACCINES 8% 46 7% 33 11% 13
VIRAL VACCINES 7% 144 6% 131 18% 13
OTHER VACCINES 24% 57 8% 37 71% 20
* 100% or over
N/A - Not Applicable
TOTAL SALES: VOLUME, PRICE, EXCHANGE
2Q `05 % CHG. VOL PX FX
TOTAL PHARMACEUTICAL SALES $ 5,468 -9% -12 1 2
U.S. ($ MM) 3,035 -12% -15 3 N/A
Foreign ($ MM) 2,433 -5% -8 -2 5

2. MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
JUNE YEAR-TO-DATE
2005
NET PRODUCT SALES DETAIL (millions of dollars)
JUNE YTD `05 vs. JUNE YTD `04
TOTAL TOTAL U.S. U.S. Foreign Foreign
PRODUCT % CHG $ % CHG $ % CHG $
AGGRASTAT 5% 46 N/A - 5% 46
ARCOXIA 16% 107 N/A - 16% 107
CANCIDAS 43% 270 33% 142 56% 128
COZAAR / HYZAAR 11% 1,504 4% 495 15% 1,009
CRIXIVAN / STOCRIN 30% 167 64% 20 27% 148
EMEND * 37 * 32 * 5
FOSAMAX 5% 1,625 1% 885 10% 739
INVANZ 52% 42 34% 26 97% 15
MAXALT 20% 162 25% 101 13% 61
PRIMAXIN 21% 366 61% 105 10% 261
PROPECIA 9% 139 4% 64 13% 75
PROSCAR 1% 363 -3% 173 5% 190
SINGULAIR 16% 1,465 12% 982 25% 483
TIMOPTIC / TIMOPTIC XE -10% 69 14% 5 -11% 63
TRUSOPT / COSOPT 11% 293 - 109 19% 184
VASOTEC / VASERETIC -12% 322 N/A - -12% 322
VIOXX * - * - * -
ZOCOR -15% 2,257 -16% 1,552 -13% 705
HEPATITIS VACCINES -21% 82 -31% 58 24% 24
VIRAL VACCINES 10% 278 7% 246 41% 32
OTHER VACCINES 15% 112 3% 76 50% 36
* 100% or over
N/A - Not Applicable
TOTAL SALES: VOLUME, PRICE, EXCHANGE
YTD `05 % CHG. VOL PX FX
TOTAL PHARMACEUTICAL SALES $ 10,830 -7% -10 1 2
U.S. ($ MM) 6,052 -10% -13 3 N/A
Foreign ($ MM) 4,778 -3% -6 -2 5

3. MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2005
OTHER (INCOME)/EXPENSE, NET (millions of dollars)
2Q `05 2Q `04 YTD 2005 YTD 2004
INTEREST INCOME $ (98.7) $ (68.5) $ (192.5) $ (134.2)
INTEREST EXPENSE 93.1 71.6 177.6 144.4
EXCHANGE (GAINS)/LOSSES (8.4) 14.9 (9.1) 7.1
MINORITY INTERESTS 30.3 36.8 60.7 76.4
Other, net (2.3) (17.3) 3.9 (329.4)
TOTAL $ 14.0 $ 37.5 $ 40.6 $ (235.7)
JOINT VENTURE SALES DETAIL (millions of dollars)
All sales reported here are end-market JV sales, presented on a quot;NETquot; basis.
YTD 2005 YTD 2004
Merial 2Q `05 2Q `04
IVOMEC, HEARTGARD, other avermectins $ 110 $ 103 $ 226 $ 196
212 184 414 345
FRONTLINE
131 110 251 223
Biologicals
60 58 115 109
Other Animal Health
11 11 20 21
Poultry Breeding
$ 523 $ 466 $ 1,027 $ 894
TOTAL MERIAL SALES
YTD 2005 YTD 2004
Sanofi Pasteur-MSD 2Q `05 2Q `04
HEPATITIS VACCINES $ 23 $ 21 $ 45 $ 41
VIRAL VACCINES 22 14 39 27
Other Vaccines 151 125 282 245
TOTAL SANOFI-MSD SALES $ 196 $ 159 $ 366 $ 313
Merck / Schering-Plough Collaboration 2Q `05 2Q `04 YTD 2005 YTD 2004
VYTORIN (Worldwide) $ 193 $ 5 $ 372 $ 5
ZETIA (Worldwide) 314 242 646 432
TOTAL $ 507 $ 247 $ 1,018 $ 437